IE
NBSE

Israel Englander’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Israel Englander’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-50
Closed -$190K – 4078
2014
Q2 		$190K Buy
+50
New +$188K ﹤0.01% 3144

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Israel Englander's NBSE Position: Q4 2022 in Review

Israel Englander sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 1,115 shares — an estimated $9K sold.

Israel Englander first reported a position in NBSE in Q1 2014 and held it in 19 quarters. The position peaked at $12.2M in Q1 2014. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

  • Israel Englander reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Israel Englander sold 1,115 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $9K.
  • Israel Englander first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 19 quarters.
  • Israel Englander's NeuBase Therapeutics, Inc. Common Stock position peaked at $12.2M in Q1 2014.
  • 34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.